1H NMR metabolomics analysis of renal cell carcinoma cells: Effect of VHL inactivation on metabolism

International Journal of Cancer

Volumn 138, Issue 10, 2016, Pages 2439-2449

  Cuperlovic Culf, Miroslava ^a,b,c   Cormier, Kevin ^b   Touaibia, Mohamed ^b   Reyjal, Julie ^b   Robichaud, Sarah ^b   Belbraouet, Mehdi ^b   Turcotte, Sandra ^b,c  

^a NATIONAL RESEARCH COUNCIL CANADA   (Canada)

^b UNIVERSITÉ DE MONCTON   (Canada)

^c ATLANTIC CANCER RESEARCH INSTITUTE   (Canada)

Author keywords

cancer metabolism; HIF; hypoxia; NMR metabolomics; RCC; renal cancer; VHL

Indexed keywords

CHOLINE; GLUTAMIC ACID; HYPOXIA INDUCIBLE FACTOR 1ALPHA; HYPOXIA INDUCIBLE FACTOR 2ALPHA; SHORT HAIRPIN RNA; VON HIPPEL LINDAU PROTEIN; BASIC HELIX LOOP HELIX TRANSCRIPTION FACTOR; ENDOTHELIAL PAS DOMAIN-CONTAINING PROTEIN 1;

AMINO ACID METABOLISM; ARTICLE; CELL METABOLISM; CITRIC ACID CYCLE; CONTROLLED STUDY; ENERGY METABOLISM; GENE SILENCING; GLYCOLYSIS; HUMAN; HUMAN CELL; METABOLOMICS; PRIORITY JOURNAL; PROTON NUCLEAR MAGNETIC RESONANCE; RENAL CELL CARCINOMA CELL LINE; SIGNAL TRANSDUCTION; CLUSTER ANALYSIS; GENETICS; KIDNEY CARCINOMA; KIDNEY TUMOR; METABOLISM; METABOLOME; MUTATION; PROCEDURES; TUMOR CELL LINE;

BASIC HELIX-LOOP-HELIX TRANSCRIPTION FACTORS; CARCINOMA, RENAL CELL; CELL LINE, TUMOR; CLUSTER ANALYSIS; GENE KNOCKDOWN TECHNIQUES; GENE SILENCING; HUMANS; HYPOXIA-INDUCIBLE FACTOR 1, ALPHA SUBUNIT; KIDNEY NEOPLASMS; METABOLOME; METABOLOMICS; MUTATION; PROTON MAGNETIC RESONANCE SPECTROSCOPY; VON HIPPEL-LINDAU TUMOR SUPPRESSOR PROTEIN;

EID: 84959917008     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.29947     Document Type: Article

References (39)

1. Sudarshan S, Karam J, Brugarolas J, et al., Metabolism of kidney cancer: from the lab to clinical practice. Eur Urol 2013; 63: 244-51.
2. Ljungberg B, Cowan NC, Hanbury DC, et al.,; European Association of Urology Guideline Group. EAU guidelines on renal cell carcinoma: the 2010 update. Eur Urol 2010; 58: 398-406.
3. Monteiro MS, Carvalho M, de Lourdes Bastos M, et al., Biomarkers in renal cell carcinoma: a metabolomics approach. Metabolomics 2014; 10: 1210-22.
4. Gerlinger M, Horswell S, Larkin J, et al., Genomic architecture and evolution of clear cell renal cell carcinomas defined by multiregion sequencing. Nat Genet 2014; 46: 225-33.
5. Kim WY, Kaelin WG., Role of VHL gene mutation in human cancer. J Clin Oncol 2004; 22: 4991-5004.
6. Moore LE, Nickerson ML, Brennan P, et al., Von Hippel-Lindau (VHL) inactivation in sporadic clear cell renal cancer: associations with germline VHL polymorphisms and etiologic risk factors. PLoS Genet 2011; 7: e1002312.
7. Turcotte S, Chan DA, Sutphin PD, et al., A molecule targeting VHL-deficient renal cell carcinoma that induces autophagy. Cancer Cell 2008; 14: 90-102.
8. Chan DA, Sutphin PD, Nguyen P, et al., Targeting Glut1 and the warburg effect in renal cell carcinoma by chemical synthetic lethality. Sci Transl Med 2011; 3: 94ra70.
9. Gatto F, Nookaew I, Nielsen J., Chromosome 3p loss of heterozygosity is associated with a unique metabolic network in clear cell renal carcinoma. Proc Natl Acad Sci USA 2014; 111: E866-E875.
10. CGARN: The Cancer Genome Atlas Research Network. Comprehensive molecular characterization of clear cell renal cell carcinoma. Nature 2013; 499: 43-9.
11. Li B, Qiu B, Lee DSM, et al., Fructose-1,6-bisphosphatase opposes renal carcinoma progression. Nature 2014; 513: 251-255.
12. Bader HL, Hsu T., Systemic VHL gene functions and the VHL disease. FEBS Lett 2012; 586: 1562-9.
13. Gameiro P, Yang J, Metelo AM, et al., In vivo HIF-mediated reductive carboxylation is regulated by citrate levels and sensitizes VHL-deficient cells to glutamine deprivation. Cell Metab 2013; 17: 372-85.
14. Wiesener MS, Jurgensen JS, Rosenberger C, et al., Widespread hypoxia-inducible expression of HIF-2alpha in distinct cell populations of different organs. FASEB J 2003; 77: 271-3.
15. Loboda A, Jozkowicz A, Dulak J., HIF-1 and HIF-2 transcription factors-similar but not identical. Mol Cells 2010; 29: 435-42.
16. Gordan JD, Bertout JA, Hu CJ, et al., HIF-2alpha promotes hypoxic cell proliferation by enhancing c-myc transcriptional activity. Cancer Cell 2007; 11: 335-47.
17. Semenza GL., Regulation of cancer cell metabolism by hypoxia-inducible factor 1. Semin Cancer Biol 2009; 19: 12-16.
18. Semenza GL., HIF-1: upstream and downstream of cancer metabolism. Curr Opin Genet Dev 2010; 20: 51-6.
19. Semenza GL., HIF-1 mediates metabolic responses to intratumoral hypoxia and oncogenic mutations. J Clin Invest 2013; 123: 3664-71.
20. Maina EN, Morris MR, Zatyka M, et al., Identification of novel VHL target genes and relationship to hypoxic response pathways. Oncogene 2005; 24: 4549-58.
21. Yuen JS, Cockman ME, Sullivan M, et al., The VHL tumor suppressor inhibits expression of the IGF1R and its loss induces IGF1R upregulation in human clear cell renal carcinoma. Oncogene 2007; 26: 6499-508.
22. Shimobayashi M, Hall MN., Making new contacts: the mTOR network in metabolism and signalling crosstalk. Nat Rev 2014; 15: 155-62.
23. Cuperlovic-Culf M, Ferguson D, Culf A, et al., 1H NMR metabolomics analysis of glioblastoma subtypes: correlation between metabolomics and gene expression characteristics. J Biol Chem 2012; 287: 20164-74.
24. Morin P, Jr, Ferguson D, LeBlanc LM, et al., NMR metabolomics analysis of the effects of 5-lipoxygenase inhibitors on metabolism in glioblasomas. J Protein Res 2013; 12: 2165-76.
25. 1H NMR metabolomics analysis of the effect of dichloroacetate and allopurinol on breast cancers. J Pharm Biomed Anal 2013; 93: 77-85.
26. Hwang T, Shaka AJ., Water suppression that works. Excitation sculpting using arbitrary waveforms and pulse field gradients. J Magn Res A 1995; 112: 275-9.
27. Savorani F, Tomasi G, Engelsen SB., Icoshift: a versatile tool for the rapid alignment of 1D NMR spectra. J Magn Reson 2010; 202: 190-202.
28. Tusher VG, Tibshirani R, Chu G., Significance analysis of microarrays applied to the ionizing radiation response. Proc Natl Acad Sci USA 2001; 98: 5116.
29. Maxwell PH, Wiesener MS, Chang GW, et al., The tumor suppressorprotein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis. Nature 1999; 399: 271-275.
30. Walker-Samuel S, Ramasawmy R, Torrealdea F, et al., In vivo imaging of glucose uptake and metabolism in tumors. Nat Med 2013; 19: 1067-72.
31. Kotze HL, Armitage EG, Sharkey KJ, et al., Novel untargeted metabolomics correlation-based network analysis incorporating human metabolic reconstructions. BMC Syst Biol 2013; 7: 107.
32. Jiang WG, Bryce RP, Horrobin DF., Essential fatty acids: molecular and cellular basis of their anti-cancer action and clinical implications. Crit Rev Oncol Hematol 1998; 27: 179-209.
33. Knox WE, Tremblay GC, Spanier BB, et al., Glutaminase activities in normal and neoplastic tissues of the rat. Cancer Res 1967; 27: 1456-8.
34. Hu H, Takano N, Xiang L, et al., Hypoxia-inducible factors enhance glutamate signaling in cancer cells. Oncotarget 2014; 5: 8853-68.
35. Long JS, Crighton D, O'Prey J, et al., Extracellular adenosine sensing-a metabolic cell death priming mechanism downstream of p53. Mol Cell 2013; 50: 394-406.
36. Antonioli L, Blandizzi C, Pacher P, et al., Immunity, inflammation and cancer: a leading role for adenosine. Nat Rev Cancer 2013; 13: 842-57.
37. Nagaya H, Gotoh A, Kanno T, et al., A3 adenosine receptor mediates apoptosis in in vitro RCC4-VHL human renal cancer cells by up-regulating AMID expression. J Urol 2013; 189: 321-8.
38. Biswas S, Troy H, Leek R, et al., Effects of HIF-1alpha and HIF2alpha on growth and metabolism of clear-cell renal cell carcinoma 786-0 xenografts. J Oncol 2010; 2010: 757908.
39. Sevcenco S, Krssak M, Javor D, et al., Diagnosis of renal tumors by in vivo proton magnetic resonance spectroscopy. World J Urol 2015; 33: 17-23.